Mizuho Securities Raises Price Target on Sucampo Pharma (SCMP) Following 3Q Beat and Raise

November 14, 2016 7:05 AM EST
Get Alerts SCMP Hot Sheet
Price: $15.20 +1.81%

Rating Summary:
    7 Buy, 4 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade SCMP Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Mizuho Securities reiterated a Neutral rating on Sucampo Pharmaceuticals (NASDAQ: SCMP), and raised the price target to $16.00 (from $13.00), following the company's 3Q earnings report. SCMP reported 3Q:16 revenue of $57.9M and $0.28 in EPS vs. consensus of $51.3M and $0.27. Management raised its 2016 revenue guidance to $220-$225M (from $195-$205M) and EPS of $1.20-$1.25 (from $0.97-$1.07).

Analyst Irina Koffler "We realize we missed the big move in the stock after a strong 3Q:16. However we see little momentum from here. We reiterate our Neutral rating and raise PT to $16 from $13."

For an analyst ratings summary and ratings history on Sucampo Pharmaceuticals click here. For more ratings news on Sucampo Pharmaceuticals click here.

Shares of Sucampo Pharmaceuticals closed at $15.20 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Earnings, Irina Koffler

Add Your Comment